Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 15, 2019
AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
BROOKLYN, N.Y., March 15, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
March 15, 2019
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate ...
March 15, 2019
Outlook Therapeutics Announces Reverse Stock Split
CRANBURY, N.J., March 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 ...
March 15, 2019
Neovasc Announces Closing of $5 Million Public Offering of Common Shares
VANCOUVER , March 15, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously ...
March 12, 2019
MediWound Announces Executive Leadership Changes
YAVNE, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe ...
March 12, 2019
AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
March 12, 2019
Krystal Biotech Reports 2018 Financial Results and Business Progress
PITTSBURGH, March 12, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases announced financial results ...
March 12, 2019
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18
HAIFA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today ...
March 12, 2019
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
TEL AVIV, Israel, March 12, 2019 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
March 12, 2019
Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
SALT LAKE CITY, March 12, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the ...
March 12, 2019
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
March 12, 2019
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
DUBLIN, March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b/3 ...
March 12, 2019
Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares
VANCOUVER, March 12, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN) announced today that it has entered into exchange agreements ("Exchange Agreements") with ...
March 12, 2019
Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28
AUSTIN, Texas, March 12, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will ...
March 12, 2019
Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ...
March 12, 2019
Altimmune Announces Closing of $14 Million Registered Direct Offering
GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct ...
March 12, 2019
Neovasc Announces Proposed Public Offering of Common Shares
VANCOUVER , March 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has commenced a ...
March 12, 2019
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018
SAN DIEGO and TORONTO, March 12, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing ...
March 12, 2019
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and ...
March 11, 2019
Genkyotex Announces Completion of 24-Week Treatment Period of Its Phase 2 Trial with GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the last patient ...
Page 37 of 169